Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

---

---

 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

---

FORM 6-K

 

---

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

Date of Report: March 30, 2023

 

Commission File Number: 001-39307

---

 

Legend Biotech Corporation

(Exact Name of Registrant as Specified in its Charter)

 

---

2101 Cottontail Lane

Somerset, New Jersey 08873

(Address of principal executive office)

 

---

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F  ☒            Form 40-F  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

---

Legend Biotech Reports Full Year 2022 Financial Results and Recent Highlights

On March 30, 2023, Legend Biotech Corporation (“Legend Biotech”) issued a press release regarding its audited financial results for the year ended December 31, 2022 and recent business highlights, which is attached to this Form 6-K as Exhibit 99.1.

This report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference in the registration statements of Legend Biotech on Form F-3 (Nos. 333-257609 and 333-257625) and Form S-8 (No. 333-239478), to the extent not superseded by documents or reports subsequently filed.

EXHIBIT INDEX

Exhibit	Title
99.1	Press Release, dated March 30, 2023

---

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	LEGEND BIOTECH CORPORATION
Date: March 30, 2023	By:	/s/ Ying Huang
	Name:	Ying Huang, Ph.D.
	Title:	Chief Executive Officer